Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5469568 | 1.00 | TLR7 (1.00) | TLR7 | |
| SCHEMBL5464741 | 0.92 | TLR7 (1.00) | TLR7 | |
| SCHEMBL5468642 | 0.92 | TLR7 (1.00) | TLR7 | |
| SCHEMBL31126375 | 0.91 | TLR7 (0.83) | TLR7 | |
| SCHEMBL20551608 | 0.91 | TLR7 (0.83) | TLR7 | |
| SCHEMBL5457983 | 0.90 | TLR7 (0.82) | TLR7 | |
| SCHEMBL5471583 | 0.90 | TLR7 (0.82) | TLR7 | |
| SCHEMBL5490042 | 0.90 | TLR7 (0.86) | TLR7 | |
| SCHEMBL4577154 | 0.90 | TLR7 (0.81) | TLR7 | |
| SCHEMBL24052315 | 0.89 | TLR7 (0.81) | TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270316-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TIANJIN LIPOGEN TECH CO LTD (CN) | 2025-08-28 | — | — | US | claimed |
| EP-4559479-A2 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-28 | — | — | EP | claimed |
| CN-117881419-A | Pharmaceutical combination and use thereof | 天津立博美华基因科技有限责任公司 | 2024-04-12 | — | — | CN | claimed |
| WO-2023274275-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | 天津立博美华基因科技有限责任公司 | 2023-01-05 | — | — | WO | claimed |
| EP-3568162-B1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | NEKTAR THERAPEUTICS (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4634153-A1 | LIPID COMPOUNDS AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250270316-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | TIANJIN LIPOGEN TECH CO LTD (CN) | 2025-08-28 | — | — | US | disclosed |
| US-20250249092-A1 | CONJUGATE OF CAPRIN-1 ANTIBODY LINKED TO IMMUNE ACTIVATOR FOR CANCER TREATMENT | TORAY INDUSTRIES, INC. (JP) | 2025-08-07 | — | — | US | disclosed |
| EP-4559479-A2 | DRUG DELIVERY COMPOSITIONS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-05-28 | — | — | EP | disclosed |
| US-12274745-B2 | Conjugate of CAPRIN-1 antibody linked to immune activator for cancer treatment | TORAY INDUSTRIES, INC. (JP) | 2025-04-15 | — | — | US | disclosed |
| WO-2025059165-A1 | METHODS OF USE FOR RHAMM-DERIVED PEPTIDES AND RHAMM-DERIVED PEPTIDE MIMETICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20250049951-A1 | NUCLEIC ACID COMPOSITIONS AND USES THEREOF | SURGE Therapeutics, Inc. | 2025-02-13 | — | — | US | disclosed |
| US-12030940-B2 | Immunotherapeutic tumor treatment method | NEKTAR THERAPEUTICS (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2024130086-A1 | LIPID COMPOUNDS AND METHODS OF MAKING AND USE THEREOF | OHIO STATE INNOVATION FOUNDATION (US) | 2024-06-20 | — | — | WO | disclosed |
| US-20230372500-A1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | NEKTAR THERAPEUTICS (US) | 2023-11-23 | — | — | US | disclosed |
| CN-116850279-A | Reductive adjuvant nano system for relieving adaptive dermatitis and application | 浙江大学 | 2023-10-10 | — | — | CN | disclosed |
| US-11744898-B2 | Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods | NEKTAR THERAPEUTICS (US) | 2023-09-05 | — | — | US | disclosed |
| US-20230181743-A1 | FUNCTIONAL LIPID DERIVATIVES AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-06-15 | — | — | US | disclosed |
| EP-4153590-A1 | FUNCTIONAL LIPID DERIVATIVES AND USES THEREOF | Ohio State Innovation Foundation (US) | 2023-03-29 | — | — | EP | disclosed |
| WO-2023274275-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | 天津立博美华基因科技有限责任公司 | 2023-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230372500-A1 | MULTI-ARM POLYMER CONJUGATES OF TLR AGONIST COMPOUNDS AND RELATED IMMUNOTHERAPEUTIC TREATMENT METHODS | TLR7, TLR8, TLR3 | TLR7 1/4885 |
| US-20250049951-A1 | NUCLEIC ACID COMPOSITIONS AND USES THEREOF | STING1, TLR9, HDGF | TLR7 188/4885 |
| US-20230181743-A1 | FUNCTIONAL LIPID DERIVATIVES AND USES THEREOF | LIPA, LIPG, LIPC | TLR7 1104/4885 |
| US-11744898-B2 | Multi-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods | TLR7, TLR8, TLR3 | TLR7 1/4885 |
| US-12030940-B2 | Immunotherapeutic tumor treatment method | CD274, TLR7, PDCD1LG2 | TLR7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.